Dermatofibrosarcoma protuberans (DFSP) – advances in diagnostics and therapy
Journal Title: OncoReview - Year 2011, Vol 1, Issue 2
Abstract
Dermatofibrosarcoma protuberans is a rare soft tissue sarcoma with a superficial growth. It has an estimated incidence of 4 cases per one million persons per year. DFSP is preferentially located on the trunk. It can appear at any age, although it is much more frequent in individuals aged between 20 and 50 years. Its growth is slow and indolent and it can last for years. With time it can accelerate and characteristic protuberant masses appear, from which the disease took its name. Distant metastases are rare, more common in the fibrosarcomatous type (FS-DFSP), with incidence of about 10% of all DFSP, and it is characterized by more aggressive behavior and poorer prognosis. In more than 95% of DFSP cases a characteristic genetic disturbance was demonstrated, which is responsible for its carcinogenesis. Translocation between chromosomes 17 and 22 results in excessive activation of PDGFRβ and in increasing of the tumor cells proliferation. Excision with wide margins is the primary treatment option for DFSP. Though improvement of surgical modalities, including microsurgery, local recurrence rates are still high. Outcomes are better with the use of postoperative radiotherapy. Using in therapy kinase inhibitor imatinib was a breakthrough in treatment of patients with locally advanced or metastatic disease. Its activity is based on inhibition of PDGFRβ activation, which is responsible for development of this tumor type.
Authors and Affiliations
Hanna Koseła, Piotr Rutkowski
Keywords
Related Articles
- EP ID EP53098
- DOI -
- Views 252
- Downloads 0
Distress and depression in cancer patients - diagnosis and treatment
Cancer diagnosis destroys previous internal and external order of patient, who has not experienced such a situation yet. The most negative emotions, which are felt in the situation of cancer diagnoses are anxiety, sadnes...
Everolimus in clinical practice. Review of German non-interventional study of everolimus in metastatic renal cell cancer after failure of initial tyrosine kinase inhibitor therapy
Everolimus is a standard for treatment of anti-vascular endothelial growth factor (VEGF)-refractory patients with metastatic renal cell carcinoma (mRCC). A German study documented mRCC patient treated everolimus from 79...
Ongoing research developments in cardio-oncology
Receptory PPAR i ich znaczenie w nowotworach
Receptory aktywowane przez proliferatory peroksysomów (ang. peroxisome proliferator activated receptor, PPAR) należą do grupy szeroko rozpowszechnionych sterydowych receptorów jądrowych. Celem pracy było przedstawienie a...
Cardioncology in Russia: Start-Off and Prospects
The progress in improving the survival of cancer patients in Russia, as well as throughout the world, means that in the next years it is going to be an increase in the number of disabled people who has achieved remission...